Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)
D Grady, D Herrington, V Bittner, R Blumenthal… - Jama, 2002 - jamanetwork.com
ContextThe Heart and Estrogen/progestin Replacement Study (HERS) found no overall
reduction in risk of coronary heart disease (CHD) events among postmenopausal women
with CHD. However, in the hormone group, findings did suggest a higher risk of CHD events
during the first year, and a decreased risk during years 3 to 5. ObjectiveTo determine if the
risk reduction observed in the later years of HERS persisted and resulted in an overall
reduced risk of CHD events with additional years of follow-up. Design and …
reduction in risk of coronary heart disease (CHD) events among postmenopausal women
with CHD. However, in the hormone group, findings did suggest a higher risk of CHD events
during the first year, and a decreased risk during years 3 to 5. ObjectiveTo determine if the
risk reduction observed in the later years of HERS persisted and resulted in an overall
reduced risk of CHD events with additional years of follow-up. Design and …